Abbott India Ltd
ABBOTINDIA NSE
Abbott India Ltd
HealthcareNSE: ABBOTINDIA BSE: 500488 Pharmaceuticals
Key Fundamentals
MidcapPharmaceuticalsHealthcareMarket Cap
₹56,863 Cr
Volatility
Moderate
P/E Ratio
34.98
EBITDA
₹2,180 Cr
Return on Equity
32.51%
Debt to Equity
0.04
Book Value
₹2,246.68
EPS
₹583.05
52W High
₹33,495
52W Low
₹25,150
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Abbott India Ltd insights
31 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 77.9%
Weaknesses
2- Stock is trading at 12.0 times its book value
- The company has delivered a poor sales growth of 9.96% over past five years.
Growth Rate
Revenue Growth
7.97% ↗
Net Income Growth
9.73% ↗
Cash Flow Change
30.38% ↗
ROE
-2.69% ↘
ROCE
-0.52% ↘
EBITDA Margin (Avg.)
2.51% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoAI opinion · based on fundamentals
Risk medium
Abbott India Ltd is a debt-free healthcare company with a market cap of ₹60,125 Cr, trading at a PE of 38.5x and delivering a consistent ROE of ~34% over 3 years. Sales growth has been moderate at 10% CAGR over 5 years while profit growth has outpaced revenue at 17% CAGR over the same period, though the stock has declined 15% over the past year.
Bull Case 8
- Virtually debt-free balance sheet provides financial resilience and flexibility for future investments
- Consistent ROE of 34-35% over 3 and 5-year periods indicates highly efficient capital allocation
- Profit CAGR of 17% over 5 years significantly outpaces sales CAGR of 10%, reflecting expanding margins and operating leverage
- Healthy dividend payout ratio of 77.9% with a current dividend yield of 2.33%, attractive for a growth company
- 10-year compounded profit growth of 20% demonstrates long-term earnings compounding ability
- 10-year stock CAGR of 20% shows sustained long-term wealth creation track record
- TTM profit growth of 11% continues to outpace TTM sales growth of 6%, suggesting ongoing margin expansion
- 10-year ROE averaging 31% indicates structural competitive advantages in its product portfolio
Bear Case 8
- Stock trades at 12.5x book value, a steep premium that leaves limited margin of safety
- Sales growth of only ~10% CAGR over 5 years is modest for a company valued at 38.5x earnings
- Stock has declined 15% over the past 1 year, underperforming broader market indices
- PE ratio of 38.5x is elevated relative to single-digit top-line growth of 6% TTM, implying a PEG well above 1
- TTM revenue growth has decelerated to 6% from the 5-year average of 10%, signaling potential slowdown
- 3-year stock CAGR of just 6% suggests the market has been re-rating the stock downward from peak valuations
- High dividend payout of 77.9% may limit reinvestment capacity for accelerating future growth
- 5-year stock CAGR of only 8% versus 17% profit CAGR indicates significant PE compression over this period
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 20h ago Positives 2
- Strong FY26 revenue growth Jul 20
Abbott India reported revenue of ₹6,929 Crores for FY 2025-26, an 8.1% year-over-year increase indicating steady top-line momentum.
- Generous dividend of ₹656/share Jul 20
The Board recommended a total dividend of ₹656 per share for FY26, signaling strong cash generation and shareholder-friendly capital allocation.
Neutral 2
- FY26 annual report shared Jul 20
Abbott India shared the web-link for its FY26 Annual Report on BSE and its company website, fulfilling routine disclosure requirements.
- BRSR filed for FY 2025-26 Jul 20
Abbott India filed its Business Responsibility and Sustainability Report for FY 2025-26, disclosing ESG metrics and sustainability initiatives as required by regulation.
TL;DR: Abbott India delivered a solid FY26 with 8.1% revenue growth to ₹6,929 Crores and a healthy ₹656/share dividend, reflecting consistent execution in the domestic pharma space. No material headwinds emerged in the latest filings. The stock benefits from predictable earnings and strong parentage, though single-digit top-line growth may limit re-rating unless volume acceleration picks up in FY27.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating Profit | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| OPM % | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% |
| Other Income | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| PBT | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% |
| Net Profit | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS in Rs | 137 | 147 | 146 | 135 | 154 | 169 | 170 | 173 | 172 | 195 | 177 | 186 | 202 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 | 7,004 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 5,037 | 5,035 |
| Operating Profit | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 | 1,969 |
| OPM % | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% | 28% |
| Other Income | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 288 | 291 |
| Interest | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 25 | 25 |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 76 | 76 |
| PBT | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 | 2,158 |
| Tax % | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | 25% | — |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 | 1,615 |
| EPS in Rs | 108 | 120 | 130 | 189 | 212 | 279 | 325 | 376 | 447 | 565 | 666 | 730 | 760 |
| Div. Payout % | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% | 90% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 4,753 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 172 |
| Other Liabilities | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,556 |
| Total Liabilities | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
| Fixed Assets | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 331 |
| CWIP | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 6,165 |
| Total Assets | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Investing | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 |
| Financing | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1,066 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 | -118 |
| Free Cash Flow | 199 | 226 | 287 | 180 | 504 | 611 | 704 | 904 | 860 | 1,165 | 960 | 1,307 |
| CFO/OP | 106 | 109 | 117 | 68 | 125 | 113 | 104 | 114 | 102 | 111 | 86 | 98 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory Days | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 | 94 |
| Days Payable | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 | 109 |
| Cash Conversion Cycle | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 | 3 |
| Working Capital Days | 30 | 32 | 21 | 63 | 22 | 10 | 4 | -7 | -8 | -14 | 99 | 2 |
| ROCE % | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% | 45% |
Documents
3
Board Meeting Outcome for Outcome Of Board Meeting
5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24. 5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil. 30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil.
5
Board Meeting Intimation for Considering Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, Along With The Audit Report Of The Statutory Auditors Thereon And To Recommend Final Dividend For The Financial Year Ended March 31, 2026.
30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend. 30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend.
Frequently Asked Questions about Abbott India Ltd
What does Abbott India Ltd do?
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Where is Abbott India Ltd (ABBOTINDIA) listed?
Abbott India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ABBOTINDIA and BSE: 500488. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Abbott India Ltd belong to?
Abbott India Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Abbott India Ltd?
Abbott India Ltd has a market capitalisation of approximately ₹56863.13 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Abbott India Ltd?
The Price-to-Earnings (PE) ratio of Abbott India Ltd is 34.98. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Abbott India Ltd?
Over the past 52 weeks, Abbott India Ltd has traded between a low of ₹25,150 and a high of ₹33,495. This range helps investors understand the stock's price volatility and recent trading levels.
Does Abbott India Ltd pay dividends?
Yes, Abbott India Ltd has a dividend yield of 2.44%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Abbott India Ltd?
Abbott India Ltd has a Return on Equity (ROE) of 32.51%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Abbott India Ltd on Tapetide?
On Tapetide, you can view Abbott India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Website abbott.co.in
CEO Mr. Kartik Rajendran
Employees 3,659
Listed 2010-01-08
Face Value ₹ 10
Issued Size 2,12,49,302